Follow up study adaptive servoventilation in HFREF

Follow up study adaptive servoventilation in HFREF - ASV_HFREF

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00011524

Enrollment

Registered

2017-01-10

Start date

2015-11-19

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

G47.3

Interventions

Group 1: - ejection fraction (EF) [%] - polysomographic investigation of the established ASV therapy (target criteria: quantitative sleep parameters, residual sleep related breathing disorder) - polys

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Therapy by a ventilator with adaptive servoventilation mode

Exclusion criteria

Exclusion criteria: Age <18 years

Design outcomes

Primary

Measure	Time frame
- therapy quality: by comparison to published normal values of quantitative sleep Parameters and sleep disordered breathing as well as by comparison to the native measurement a decision could be made whether the established ASV therapy or the APAP therapy provides a better therapy quality (polysomographic investigation) - patient decision: after explaining the risk factors for ASV usage as published in the SERVE-HF study and explaining the results of our investigations to the patient the patient could decide between three possibilities for future treatment: discontinuation of the therapy, Switch to the alternative APAP therapy, go on with the established ASV therapy	—

Measure

Time frame

- therapy quality: by comparison to published normal values of quantitative sleep Parameters and sleep disordered breathing as well as by comparison to the native measurement a decision could be made whether the established ASV therapy or the APAP therapy provides a better therapy quality (polysomographic investigation) - patient decision: after explaining the risk factors for ASV usage as published in the SERVE-HF study and explaining the results of our investigations to the patient the patient could decide between three possibilities for future treatment: discontinuation of the therapy, Switch to the alternative APAP therapy, go on with the established ASV therapy

—

Secondary

Measure	Time frame
- sleep quality: by comparison to published normal values of quantitative sleep parameters sleep quality in the individual patient can be determined - number/proportion of therapy discontinuation: patients who decide for discontinuation of therapy at all (ASV as well as APAP)	—

Countries

Germany

Contacts

Public ContactDominic Dellweg

Fachkrankenhaus Kloster Grafschaft GmbH

d.dellweg@fkkg.de02972-79100

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026